Skip to content
Veracyte® Investor Relations
Veracyte is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment.
The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California.

Veracyte® Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
Meta-analysis of 13 independent studies suggests genomic test performs even better in real-world clinical practice as compared to original clinical validation study SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 15, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced that findings
Toggle Summary Veracyte Announces Third Quarter 2022 Financial Results
Grew Total Revenue to $75.6 million , an Increase of 25% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2022-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2022 .


There are currently no events to display.


Title Documents

Corporate Presentation November 2022